CCI
A fresher price tag
BMO Capital just nudged Crown Castle’s price target up to $100 from $91 and left its Outperform rating intact. In analyst-speak, that’s basically: “We still like the stock, and now we like it a little more.”
Not the only opinion in the room
This wasn’t a unanimous lovefest, though. Citizens kept its Market Outperform call with a beefier $125 target, while Wells Fargo went the other way, cutting Crown Castle to Equal Weight from Overweight and trimming its target to $85.
Why investors should care
That kind of split screen matters. When analysts start arguing over a name this loudly, it usually means the market is still trying to price in the company’s growth runway, cash flow profile, and how much faith to place in its organic growth story versus peers.
The takeaway
For you, the big question is whether Crown Castle can keep convincing Wall Street that the upside is real enough to justify higher targets — or whether the skeptics get the last word. Big picture: the stock still has believers, but the analyst community is clearly not singing from the same hymnal.